CASE SERIES

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy

Evert S. M. van Aken1 | Aart Beeker2 | Ilse Houtenbos2 | Floris J. Pos1 | Sabine C. Linn3 | Paula H. M. Elkhuizen1 | Monique C. de Jong1

1Department of Radiation Oncology, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands
2Department of Medical Oncology, Spaarne Gasthuis, Hoofddorp, The Netherlands
3Department of Medical Oncology, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands

Correspondence
Evert S. M. van Aken, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Email: e.v.aken@nki.nl

Abstract
Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors have recently been approved for the treatment of hormone receptor–positive and HER2-negative metastatic breast cancer in association with endocrine therapy in postmenopausal women. Data on the interaction of CDK4/6 inhibition and radiotherapy are scarce, but some studies show unexpected toxicity.

Cases: We report three cases of unexpected severe or prolonged soft tissue, skin, and gastrointestinal toxicity in patients treated with a combination of radiotherapy and the CDK4/6 inhibitor palbociclib.

Conclusion: These cases indicate a possible interaction between radiotherapy and palbociclib. Therefore, we recommend using radiotherapy cautiously when combined with CDK4/6 inhibitors.

KEYWORDS
breast cancer, clinical observations, radiation therapy, targeted therapy

1 | BACKGROUND

Cyclin-dependent kinase (CDK) 4/6 inhibitors like abemaciclib, ribociclib, and palbociclib have recently been approved for the treatment of hormone receptor–positive and HER2-negative metastatic breast cancer in combination with endocrine therapy in postmenopausal women.1-3 Many of these women are candidates for radiotherapy during palbociclib use due to (oligo)progression or local complaints.4 However, data on the interaction between CDK4/6 inhibition and radiotherapy are scarce.

Several small series of patients receiving radiotherapy during treatment with a CDK4/6 inhibitor have been published. Most of these series do not report unexpected toxicity for the combination of CDK4/6 inhibitors and radiotherapy.5-12 Nevertheless, grade 3 (G3) skin and gastrointestinal toxicity are reported for the combination of radiotherapy and CDK4/6 inhibitors.13,14 Two case reports describe a G3 colitis after 10 × 3 Gy while on palbociclib.13,14 Two retrospective studies show that the combination is generally safe, but the authors also report a G3 ileitis in one patient (10 × 3 Gy) and G3 skin toxicity in two patients (radiation dose not mentioned).15,16 Grade 3 esophagitis is described in two case reports (30 × 2 Gy and 5 × 4 Gy), combined with G3 dermatitis in one patient.17,18 Also, a conference abstract reports unexpected pronounced pulmonary fibrosis and radiation pneumonitis.19 We present three patients with unexpected toxicity after radiotherapy in combination with palbociclib (Table 1), which indicates a possible severe interaction between these treatments.

2 | CASES

2.1 | Patient 1

A 64-year-old woman with recently diagnosed bone metastases of a previously treated breast cancer was treated with letrozole and...
palbociclib. Two months after the start of systemic treatment, palliative radiotherapy (20 Gy in 5 fractions, once daily) was prescribed to symptomatic bone metastases in the right pelvis, using two opposing 10 MV fields. An EQD2, $\alpha/\beta = 10$ Gy (equivalent dose in 2-Gy fractions) of 23 Gy was delivered to bowel loops inside the field. Palbociclib was continued during radiotherapy. Days after the last fraction, our patient experienced a severe enterocolitis, for which she was hospitalized for 10 days. On a diagnostic computed tomography (CT), bowel loops inside the radiotherapy field were clearly swollen (Figure 1). Treatment consisted of analgesics, antibiotics, and nil per os. Two months after radiotherapy, she was still not fully recovered, with occasional diarrhea and use of fortified drinks.

### 2.2 Patient 2

A 60-year-old woman with metastatic breast cancer was treated with fulvestrant and palbociclib. At the start of her systemic treatment, she received palliative radiotherapy (8 Gy in a single fraction, field shown in Figure 2A) to a painful bone metastasis in the left hip, resulting in a short-term reduction of pain. Hoping to increase effectiveness, she received a second course of radiotherapy 2 months later (16 Gy in two fractions). Radiotherapy was administered using two opposing fields (10 MV), resulting in a total dose just below the skin of EQD2, $\alpha/\beta = 3.2$ Gy, 32 Gy, increasing to 53 Gy around the femur.

Four months after the last radiotherapy, she experienced edema, redness, and pain of her left upper leg/hip. A deep venous thrombosis was excluded, and treatment with antibiotics had no effect. Clinical photographs taken 5 months after the completion of the second radiotherapy course show clear evidence of skin discoloration and induration within the radiation field (Figure 2E,F). An FDG PET/CT (fluorodeoxyglucose positron emission tomography combined with computed tomography) showed no evidence of disease progression, but a moderate generalized uptake of FDG around the left hip (Figure 2B). Various MRI (magnetic resonance imaging)
imaging) sequences showed increased signal intensity in the area of the original radiotherapy field, most pronounced on the gadolinium-enhanced T1-weighted SPAIR (spectral-attenuated inversion recovery) MRI (Figure 2C,D). Six months after radiotherapy, she was using an equivalent of more than 250 mg oral morphine per 24 h and 20 mg of prednisone, resulting in some reduction of swelling but no satisfactory pain relief.

2.3 | Patient 3

A 58-year-old woman with metastatic breast cancer was treated with fulvestrant and palbociclib. In the past, she was treated with 50 Gy (tangential fields) + 15 Gy electron boost to the left breast. For this treatment, a substantial dose to the esophagus is very unlikely. Fourteen years later, she was treated with 46 Gy (fractions of 2 Gy) reirradiation combined with superficial hyperthermia to the left thoracic wall and parasternal lymph nodes because of tumor recurrence. The estimated EQD$_{2,α/β}$ = 10 Gy, to the mid-thoracic esophagus was 21 Gy. Because of hilar and mediastinal oligoprogression during fulvestrant and palbociclib 5 years later, she received radiotherapy (17 × 3 Gy, once daily, field shown in Figure 3A,B) to the mediastinum and right hilum, using volumetric modulated arc therapy (VMAT). The V$_{50α/β}$ = 10 Gy (relative volume receiving an EQD$_{2,α/β}$ = 10 Gy of at least 50 Gy) was 13.3%, correlating with a G > 2 esophagitis risk of around 25%.$^{20}$ Palbociclib was stopped 3–4 days before radiotherapy and restarted 8–9 days after the last fraction. During the radiotherapy treatment, she developed progressive dysphagia with an inadequate response to analgesics and sucralfate. After an initial slight improvement at 2 weeks after radiotherapy, symptoms worsened and did not improve with pantoprazole. An esophagoscopy was performed 3 months after the last radiotherapy, showing an ulcer with a pinpoint stenosis (Figure 3C). The location of the ulcer corresponded with the high-dose region of the last radiotherapy course.$^{21}$ A biopsy was taken and showed squamous epithelium with some inflammation and neither dysplasia nor carcinoma. Palbociclib was then stopped, which resulted in a gradual improvement of her symptoms. A second esophagoscopy was performed 1.5 months later, which only showed a small, superficial ulcer and a decrease of the stenosis (Figure 3D). Palbociclib was restarted 5.5 months after the last radiotherapy, following a third esophagoscopy, which showed visible improvement (Figure 3E). Palbociclib was continued for five more months until disease progression, without new worsening of her symptoms.

3 | DISCUSSION

We present three cases of unexpected severe or prolonged soft tissue, skin, and gastrointestinal toxicity that occurred in patients receiving palbociclib and radiotherapy. We did not discover alternative explanations for the observed toxicities. Dose delivery during treatment was verified using electronic portal image dosimetry and was delivered as planned. Side effects were only present inside the radiotherapy field and are extremely uncommon for equivalent doses to bowel and soft tissue/skin in the first two cases. In the third case, dysphagia was not unexpected (especially not after previous radiotherapy), but the recovery pattern was unusual. An initial recovery was followed by worsening after restart of palbociclib, and improvement was seen only after discontinuation of palbociclib. This emphasizes the possible negative role of palbociclib during repopulation of healthy tissues after radiotherapy.

A pre-existing increased intrinsic sensitivity to ionizing radiation is highly unlikely in these patients, since they had radiotherapy for their primary breast cancer without serious unexpected toxicity, and there were no known risk factors for increased radiotherapy toxicity. Additionally, there was no reason to assume different pharmacodynamics in these patients.

It is worth noting that the patients in this case series received hypofractionated radiotherapy, which may lead to a less beneficial therapeutic ratio with regard to normal tissue complications, but this is particularly the case for late-responding tissues.$^{22,23}$ Furthermore, hypofractionated radiotherapy is often applied...
as a convenient and effective therapy for palliative treatment indications.\textsuperscript{22}

In the introduction, we summarized the literature regarding the combination of radiotherapy with CDK4/6 inhibitors. The observations in our case series are in line with previous reports showing several cases of G3 skin and gastrointestinal toxicity.\textsuperscript{13–18} However, the nature and limited size of these studies, including our study, make it difficult to reliably predict the absolute risk of increased toxicity.

3.1 | Possible (radio)biological mechanism

Palbociclib is a CDK4/6 inhibitor that inhibits cell division by causing a G1/S block.\textsuperscript{24} While this is advantageous for the elimination of fast-dividing cancer cells, cell division is pivotal to repair/repopulate normal tissues after radiotherapy. Inhibition could therefore lead to increased and prolonged normal tissue damage. Although the main mechanism of palbociclib is cell cycle inhibition, the possibility of radiosensitization by an off-target effect cannot be excluded. A report
CONCLUSION

We present two cases suggesting severe unexpected normal tissue radiosensitization by palbociclib and one case with delayed recovery from acute normal tissue toxicity by palbociclib. We recommend using radiotherapy cautiously when combined with CDK4/6 inhibitors. If palbociclib is discontinued during radiotherapy, withholding palbociclib until recovery from acute radiotherapy toxicity appears sensible. As the number of women on CDK4/6 inhibitors increases, both medical and radiation oncologists should be aware of a possible interaction when patients are referred for radiotherapy.

CONFLICT OF INTEREST

S.L. is an advisory board member for AstraZeneca, Cergentis, IBM, Pfizer and Roche and received grants paid to the institute from Agendia, AstraZeneca, Eurocept-pharmaceuticals, Genentech, Novartis, Pfizer, Roche, Tesaro, and Immunomedics outside of this study. In addition, S.L. received institutional nonfinancial support from Agendia, AstraZeneca, Bayer, Daiichi-Sankyo, Genentech, IBM, Immunomedics, Novartis, Pfizer, Roche, and Tesaro outside of this study. The other authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

All authors had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Conceptualization, A.B., I.H., F.P., S.L., P.E., M.J.; Data Curation, E.A., M.J.; Visualization, E.A., M.J.; Writing-Original Draft, E.A., M.J.; Writing-Review & Editing, E.A., A.B., I.H., F.P., S.L., P.E., M.J.

ETHICAL STATEMENT

All patients agreed to anonymized publication of their data. As this is a case series, no institutional approval was required. All authors contributed to the collection of the data, the analysis of the data, and the writing of this manuscript. All authors had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

DATA AVAILABILITY STATEMENT

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

ORCID

Evert S. M. van Aken https://orcid.org/0000-0003-2358-4435

REFERENCES

1. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of
hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phas. Lancet Oncol. 2016;17:425-439.

2. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016; 375:1738-1748.

3. Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35: 3638-3646.

4. Lieve S, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157-166.

5. Hans S, Cott P, Kirova YM. Preliminary results of the association of Palbociclib and radiotherapy in metastatic breast cancer patients. Radiother Oncol. 2018;126:181.

6. Meantini I, Desideri I, Scotti V, Simontacchi G, Livi L. Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer. Breast. 2018;42:1-2.

7. Figura NB, Poturi TK, Mohammadi H, et al. CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases. J Neurooncol. 2019;144:583-589.

8. Ippolito E, Greco C, Silipigni S, et al. Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: preliminary assessment of toxicity. Breast. 2019;46:70-74.

9. Beddok A, Xu HP, Henry AA, et al. Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature. Br J Cancer. 2020;123:905-908.

10. Ratao S, Orazem M, Scocimarro E, et al. Cyclin-dependent kinase 4/6 inhibitors combined with radiotherapy for patients with metastatic breast cancer. Clin Breast Cancer. 2020;20:495-502.

11. Stauder MC, Tereffe W, Shaitelman SF, et al. Toxicity of radiation therapy given concomitantly with Palbociclib for metastatic breast carcinoma. Int J Radiat Oncol. 2019;105:E60.

12. Chowdhury M, Sen N, Chowdhury A, et al. Safety and efficacy of Palbociclib and radiation therapy in patients with metastatic breast cancer: initial results of a novel combination. Adv Radiat Oncol. 2019;4:453-457.

13. Kawamoto T, Shikama N, Sasai K. Severe acute radiation-induced enterocolitis after combined palbociclib and palliative radiotherapy treatment. Radiother Oncol. 2019;131:240-241.

14. Dasgupta A, Sahgal A, Warner E, Czarnota GJ. Safety of palbociclib concurrent with palliative pelvic radiotherapy: discussion of a case of increased toxicity and brief review of literature. J Med Radiat Sci. 2021;68:96-102.

15. Guerini AE, Pedretti S, Salah E, et al. A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients. Sci Rep. 2020;10:13589.

16. Howlett S, Harvey-Jones E, Smith D, et al. Does concurrent use of CDK4/6 inhibitors during palliative radiotherapy increase toxicity in patients with metastatic breast cancer? Clin Oncol. 2021;33:e99.

17. Messer JA, Ekinci E, Patel TA, Teh BS. Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: a case report. Reports Pract Oncol Radiother. 2019;24:276-280.

18. Nasir UM, Mozek AM, Sayan M, et al. Severe gastrointestinal mucositis following concurrent Palbociclib and palliative radiation therapy. Anticancer Res. 2020;40:5291-5294.

19. Kalash R, Iarrobino NA, Beriwal S, Sun M, Glaser SM, Champ CE. Palbociclib enhances pulmonary fibrosis in patients undergoing thoracic radiation therapy: a case series and review of the literature. Int J Radiat Oncol. 2018;102:e610.

20. Werner-Wasik M, Yorke J, Deasy J, Nam J, Marks LB. Radiation dose-volume effects in the esophagus. Int J Radiat Oncol. 2010;76: S86-S93.

21. Emura F, Gomez-Esquivel R, Rodriguez-Reyes C, et al. Endoscopic identification of endoluminal esophageal landmarks for radial and longitudinal orientation and lesion location. World J Gastroenterol. 2019; 25:498-508.

22. Lutz ST, Chow EL, Hartsell WF, Konski AA. A review of hypofractionated palliative radiotherapy. Cancer. 2007;109:1462-1470.

23. Nahum AE. The radiobiology of Hypofractionation. Clin Oncol. 2015; 27:260-269.

24. Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A. CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought. Cancer Cell. 2018;34:9-20.

25. Huang C-Y, Hsieh F-S, Wang C-Y, et al. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response. Eur J Cancer. 2018;102:10-22.

How to cite this article: van Aken ESM, Beeker A, Houtenbos I, et al. Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy. Cancer Reports. 2021;e1470. https://doi.org/10.1002/cnr2.1470.